Current Unknowns and Future Opportunities with IDH-Inhibitor Therapy

UCSF neuro-oncologist Jennie Taylor, MD, MPH discusses how the role for treatment with vorasidenib prior to surgery and at recurrence remains unclear. Researchers and physicians also do not know yet if IDH inhibitor therapy helps patients live longer.